Clinical trial
A Phase III, Multicenter, Randomized Study to Assess the Efficacy and Safety of 0,5 mg Tizaspray® Administered Intranasally Versus Sirdalud® 2 mg Tablets, in Patients With Acute Low Back Pain
NCT02934061 is registered in ClinicalTrials.gov with MDM S.p.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Multicenter, Randomized Study to Assess the Efficacy and Safety of 0,5 mg Tizaspray® Administered Intranasally Versus Sirdalud® 2 mg Tablets, in Patients With Acute Low Back Pain
- Lead sponsor
- MDM S.p.A.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2016
- Completion date
- February 28, 2017
- Enrollment
- 117 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.